On this page

Are dopamine agonists good for the restless legs syndrome?

Dopamine agonists are now second line therapy for RLS. Their use is primarily when gabapentinoids are contraindicated.

Historically, dopamine agonists (like Sifrol, ropinirole, or the rotigotine patch) were the absolute first-line treatment choice for Restless Legs Syndrome (RLS). However, due to the risk of long-term augmentation (where the drug makes the RLS worse), modern medical guidelines, including those from the American Academy of Sleep Medicine, have shifted significantly. Currently, gabapentinoids (gabapentin enacarbil, standard gabapentin, and pregabalin) are preferred as the first-line treatment for most patients. Even with this shift, there are still specific clinical scenarios where a doctor may choose a dopamine agonist over gabapentinoids in the treatment of RLS. Reasons for using a dopamine agonist over gabapentinoids are located in the Gabapentinoids page under the heading "Contraindications for gabapentinoids". A summary is located in Box 1.

Depression and / or anxiety
Falls risk / unsteadiness
Severe lung disease or sleep apnoea
History of severe weight gain or lower leg edema
Failure or intolerance to gabapentinoids

Box 1 : Contraindications for gabapentinoids

Sifrol calms the brain sending signals that help regulate smooth, controlled muscle movements soothing those frantic, uncomfortable urges in the legs. Sifrol is cleared almost entirely by the kidneys requiring careful dosing if kidney function is reduced.

Sifrol dosing

The typical starting dose is 0.125 mg and can incremented up to a maximum of 0.5 mg. It is typically taken once daily, about 2 to 3-hours before bedtime, or whenever symptoms usually begin to appear. While Sifrol is prescribed in much higher doses for conditions like Parkinson's disease (up to 4.5 mg per day), the absolute maximum dose for RLS is strictly 0.5 mg per day. Going over this limit heavily increases the risk of severe complications. Most people notice a significant reduction in symptoms within the first few days of treatment.

Sifrol side effects

When first starting Sifrol or increasing the dose for RLS, side effects are usually mild to moderate and often improve as your body adjusts. Side effects include:

Nausea: This is very common, affecting up to 15% to 20% of users initially. Taking the medication with a light snack can help minimize it.
Sleepiness: In some cases, users may experience "sleep attacks" or extreme drowsiness during the day.
Headache: Frequently reported during the first few weeks.
Dizziness or Lightheadedness: Sifrol can lower blood pressure slightly, especially when moving from a sitting or lying position to standing (orthostatic hypotension).
Insomnia or Vivid Dreams: Paradoxically, while it stops the leg twitching, it can occasionally disrupt your sleep architecture or give you wild, memorable dreams.
Impulse Control Issues: These are a rare but notable side effect of dopamine agonists. A change in behavior, such as increased gambling, shopping, hypersexuality, or binge eating have been noted due to the drug’s effect on the brain's reward system.
Augmentation: The most significant long-term concern with Sifrol is a phenomenon called augmentation. This occurs when the medication, over time, actually makes RLS symptoms worse.

Sifrol anchor

Sifrol (Pramipexole) in the restless legs syndrome

Never stop taking Sifrol suddenly or change your dose on your own, as sudden withdrawal can trigger severe rebound symptoms and intense insomnia. Always collaborate with your prescribing doctor.

Note

Sifrol was first officially approved in 2006 by the FDA (USA), TGA (Australia) and the EMA (Europe) as a treatment for Restless Leg Syndrome (RLS). Although it had been used off label by some clinicians prior to that. Sifrol was once the first-line treatment for RLS however now, due to sifrol side effects, gabapentinoids are first-line treatments.

Sifrol is a common prescription medication used to manage RLS. Sifrol is a dopamine agonist. It works by binding to dopamine receptors (specifically the D2 and D3 receptor subtypes) in the basal ganglia (specifically the striatum), in the limbic system and the Diencephalospinal Pathway (Midbrain to Spinal Cord). Sifrol tricks the brain into thinking there is plenty of dopamine available restoring steady, stable signaling.

Figure 1: Sifrol tablet pack

Augmentation of RLS symptoms due to dopamine agonists

Augmentation occurs in 42% to 70% of patients treated with dopamine agonists during 8 to 10-years, equivalent to a rate of 5% to 7% per year. The risk of augmentation can be reduced by keeping the dose of dopamine agonists low. Patients should be informed about the symptoms of augmentation and the clinician should ask about signs of augmentation at every visit to facilitate early detection.

Signs of augmentation include:

Symptoms starting earlier in the day (e.g., in the afternoon instead of the evening).
The sensations spreading to other parts of the body, like the arms, trunk or other areas.
The medication taking longer to kick in.
Symptoms become more intense.
Relief from each dose becomes shorter.
The patient needs the medicine earlier or requires progressively higher doses.
Increasing the dopamine agonist produces only brief improvement followed by further worsening.

The management of augmentation is at the end of this dopamine agonist section.

Ropinirole anchor

Ropinirole (Requip) in the treatment of restless legs syndrome

Ropinirole belongs to the same class of medication as Sifrol being dopamine agonists. Ropinirole is primarily used to treat RLS and Parkinson’s disease. Just like Sifrol, it works by tricking the brain into thinking more dopamine is available. It binds primarily to D2 and D3 dopamine receptors in the basal ganglia and the diencephalospinal pathway, smoothing out movement control and quietening down the overactive sensory signals in the spinal cord that cause the classic "creepy-crawly", "urge to move" RLS sensations.

Ropinirole is approved by both the Therapeutic Goods Administration (TGA) in Australia and the FDA in the United States specifically for moderate-to-severe primary RLS.

Ropinirole is broken down by the liver (CYP1A2 enzyme). It can interact with other liver-processed drugs (like ciprofloxacin or smoking, which affects the enzyme).

Ropinirole dosing

For RLS, Ropinirole is typically taken once daily, roughly 1 to 3-hours before bedtime. Doctors usually start patients on a very low dose (0.25 mg) and gradually increase it over several weeks to find the effective level while minimizing side effects. A dose of 2.0 mg is the average effective dose found in most clinical trials.

If symptoms persist after 4-weeks of titration, and the medication is being well tolerated, a physician may continue to raise the daily dose by 0.5 mg increments each week (e.g., 2.5 mg in Week 5, 3.0 mg in Week 6) up to a maximum recommended dose of 4.0 mg once daily.

Figure 2: Box of Ropinirole tablets

Ropinirole side effects

While effective, Ropinirole can cause several side effects, particularly when starting the medication or increasing the dose:

Nausea and Vomiting: Often the most common complaint; taking it with food can help.
Drowsiness/Sleepiness (Somnolence): While it helps you sleep through the night, daytime grogginess or fatigue can spill over into the next day. Some users experience "sleep attacks," where they fall asleep suddenly during the day.
Headache: Mild to moderate headaches are frequently reported during the initial titration phase (the period when your doctor slowly bumps up the dose).
Dizziness or Light-Headedness: Particularly when standing up quickly (orthostatic hypotension).
Augmentation: This is a paradoxical reaction where, over time, the RLS symptoms actually get worse.
Impulse Control Disorders: Some patients experience intense urges to gamble, spend money, binge eat, increased sexual urges or engage in other repetitive behaviours.

The timing of restless legs syndrome (RLS) isn't random it is in part due to the internal body clock. Did you know that the body has in own clock? The circadian pacemaker, that controls many biological systems, is located in the suprachiasmatic nucleus (SCN), a tiny region of the brain sitting in the hypothalamus. The SCN synchronises rhythms in a 24-hour cycle. Light is important in setting the SCN rhythm. The circadian rhythm governs the sleep/wake cycle but also influences body temperature (which typically hits its lowest point in the early morning and peaks in the late afternoon). The SCN controls hormone release (the timing of melatonin cycle [the "sleep hormone"] and cortisol (the "wakefulness hormone"). The SCN also influences digestion. The metabolism is more efficient at processing food during daylight hours, as your body is biologically primed to handle caloric intake when it is active. The body clock regulates enzymes such as tyrosine hydroxylase, required to synthesize dopamine. There is an night time dip in tyrosine hydroxylase leading to decreased dopamine worsening RLS. Genetic variations cause people to have different cycles "chronotypes." Some individuals have a naturally shifted rhythm that causes them to reach their peak alertness early in the morning, while others are biologically programmed to feel most productive and alert late at night. This is not just a preference; it is a genetically influenced variation in internal timing. To keep your clock healthy get some sunshine in the morning. Keep a regular bedtime and wake time.

Rotigotine anchor

The use of Rotigotine (Neupro) for restless legs syndrome

Rotigotine belongs to the same class of medication as Sifrol and Ropinirole being a dopamine agonist. Rotigotine is used to treat RLS, but it has a distinct delivery method that sets it apart from oral medications like Sifrol and Ropinirole. It is administered via a 24-hour transdermal (skin) patch rather than a pill. Rotigotine is often considered when:

A patient has difficulty swallowing pills.
RLS symptoms are present throughout the day, not just at night.
A patient experiences significant "rebound" symptoms as their evening dose of oral medication wears off.

Benefits of transdermal administration

Because Rotigotine is absorbed through the skin, it provides continuous 24-hour medication delivery. Unlike pills that cause "peaks and valleys" in blood concentration, the patch maintains a stable level of the drug in the system. This continuous delivery can be particularly helpful for patients who experience RLS symptoms during the day or very early in the morning (morning rebound).

Figure 3: Rotigotine transdermal patch

Rotigotine dosing

The patch is applied once daily to clean, dry skin (usually on the abdomen, thigh, hip, or shoulder). It should be moved to a different spot every day to prevent skin irritation. You shouldn't use the same spot twice within 14 days.c An initial strength of 1 mg and a maximum strength of 3 mg is used.

Rotigotine side effects

Rotigotine shares the typical side effects of dopamine agonists, with one unique addition being application site reactions. Possible side effects are:

Application Site Reactions: This is the most common side effect. Redness, itching, or swelling can occur where the patch is placed.

Nausea: Similar to Ropinirole, though sometimes less intense due to the lack of "peaks" in drug levels.
Sleepiness, Drowsiness and General Tiredness (Somnolence): Are frequently reported, as the continuous 24-hour delivery means the dopamine pathways are continuously stimulated day and night.
Dizziness or Light-headedness: Potential dizziness when standing up quickly (orthostatic hypotension).
Augmentation: This is a paradoxical reaction where, over time, the RLS symptoms actually get worse. While Rotigotine is a dopamine agonist, some studies suggest the risk of augmentation may be slightly lower (or delayed) compared to short-acting oral agonists because of the stable, continuous delivery. However, it is still a significant risk.
Impulse Control Disorders: Some patients experience intense urges to gamble, spend money, binge eat, increased sexual urges or engage in other repetitive behaviours.

Did you know that humans are the only mammals that delay sleep. We are the only species that intentionally puts off sleeping for other activities, such as working, socializing, or using technology.

During REM (rapid eye movement) sleep, the brain releases chemicals that temporarily paralyze the muscles. This is known as "atonia". This muscle paralysis has evolved to prevent you from physically acting out your dreams and potentially hurting yourself.

The management of patients with augmentation of RLS symptoms from dopamine agonists

If augmentation is suspected the first step is to reassess iron stores and if warranted give IV iron. There are 2 approaches not to be taken in response to augmentation. These are:

1. Do not increase the dose of the dopamine agonist to ameliorate the symptoms. In the very short-term increasing the dose may help but it will lead to worsening of symptoms.

2. Do not suddenly cease the dopamine agonist as this can lead to:

Severe RLS symptoms
Profound insomnia
Anxiety, agitation, depression or suicidal ideation
Symptoms throughout much of the day

For many patients with augmentation a low-dose opioid or Gabapentinoid (if not previously unsuccessful) is introduced before or while the dopamine agonist is reduced.

A common approach is cross-titration:

Introduce and gradually adjust the replacement treatment.
Begin slowly reducing the dopamine agonist.
Continue the overlap while monitoring symptoms, sleep and mood.
Slow or temporarily pause the taper if withdrawal becomes intolerable.
Once the dopamine agonist is completely withdrawn consider reducing the dose of low-dose opioid or Gabapentinoid.

The 2021 Mayo/RLS Foundation algorithm states that reductions should not exceed steps of 0.25 mg of pramipexole or 0.5 mg of ropinirole or 1 mg rotigotine patch no shorter than every three days and up to 1-month. These are maximum reduction rates, not mandatory schedules and many patients require a considerably slower, individualised taper.

A carefully selected low-dose opioid may be required when symptoms are severe or when a gabapentinoid cannot adequately cover dopamine agonist withdrawal. The AASM notes that opioids can facilitate tapering and sometimes become the continuing treatment for severe augmented RLS.

Low-dose opioids requires assessment of:

Sleep apnoea and respiratory disease
Sedatives and other respiratory depressants
Previous substance use problems
Constipation, falls and cognitive effects
Drug interactions and local prescribing requirements

Severe or widespread augmentation usually warrants referral to a neurologist or sleep physician experienced in RLS.

Augmentation management

Do not begin, stop or change an RLS medicine without advice from your doctor or pharmacist.

For other treatment options see the pages:

In some instances when you see a doctor for restless legs syndrome (RLS) they will order a sleep test which is called polysomnography. Quite simply "poly" means many, "somno" means sleep and "graphy" means recordings. So put together polysomnography means "many sleep recordings". In a sleep study typically you have some electrodes on your head (EEG), electrodes on the outside of the eyes (electro-oculogram [EOG]) to measure eye movement (helps detection of REM sleep), a thermistor (temperature probe under your nose (measures air flow - useful in detecting sleep apnoea), belts around the chest and abdomen (measure the action of breathing), sometimes electrodes on the legs (measure leg muscle activation - useful for detecting the periodic limb movement syndrome [PLMS]). Also possible are some electrodes on your chest to measure your heart rhythm (ECG). Lastly there is an oximeter attached to a finger (measures blood oxygen - useful in the detection of sleep apnoea).

Last edited: 18/09/2026